Using PARP Inhibitors in Frontline Maintenance Therapy of Ovarian Cancer

Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.

EP. 1: Genetic Testing for Ovarian Cancer

January 20th 2021

EP. 2: Role of Maintenance Therapy in Ovarian Cancer

January 20th 2021

EP. 3: Ovarian Cancer: FDA Approved PARP Inhibitors

January 20th 2021

EP. 4: SOLO-1 Trial

January 20th 2021

EP. 5: PRIMA Trial

January 20th 2021

EP. 6: PAOLA-1 Trial

January 20th 2021

EP. 7: Selecting Maintenance Therapy in Ovarian Cancer

January 20th 2021

EP. 8: Role of PARP Inhibition in Recurrent Ovarian Cancer

January 20th 2021

EP. 9: Future Directions for Treatment of Ovarian Cancer

January 20th 2021